Trial register facet
Trial records for Tesamorelin
16 records for Tesamorelin, of which 3 are published trials.
Showing 0 records on this page
Records
16 documents
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| TESA-NAFLD-PH2 | Tesamorelin | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 61 | 2019 | Low |
| TESA-NAFLD-PH2-PKprogramme record | Tesamorelin | Phase 1 | Reported | Phase 1 ascending dose | — | 2019 | Very low |
| TESA-NAFLD-PH2-RENAL-IMPprogramme record | Tesamorelin | Phase 1 | Reported | Phase 1 ascending dose | — | 2019 | Very low |
| TESA-NAFLD-PH2-HEPATIC-IMPprogramme record | Tesamorelin | Phase 1 | Reported | Phase 1 ascending dose | — | 2019 | Very low |
| TESA-NAFLD-PH2-BODY-COMPprogramme record | Tesamorelin | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| TESA-PIVOTAL-1 | Tesamorelin | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 412 | 2010 | Moderate |
| TESA-PIVOTAL-2 | Tesamorelin | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 404 | 2010 | Moderate |
| TESA-PIVOTAL-1-DDIprogramme record | Tesamorelin | Phase 1 | Reported | Randomised crossover | — | 2010 | Very low |
| TESA-PIVOTAL-2-PKprogramme record | Tesamorelin | Phase 1 | Reported | Phase 1 ascending dose | — | 2010 | Very low |
| TESA-PIVOTAL-1-HEPATIC-IMPprogramme record | Tesamorelin | Phase 1 | Reported | Phase 1 ascending dose | — | 2010 | Very low |
| TESA-PIVOTAL-2-RENAL-IMPprogramme record | Tesamorelin | Phase 1 | Reported | Phase 1 ascending dose | — | 2010 | Very low |
| TESA-PIVOTAL-1-RENAL-IMPprogramme record | Tesamorelin | Phase 1 | Reported | Phase 1 ascending dose | — | 2010 | Very low |
| TESA-PIVOTAL-2-HEPATIC-IMPprogramme record | Tesamorelin | Phase 1 | Reported | Phase 1 ascending dose | — | 2010 | Very low |
| TESA-PIVOTAL-1-PKprogramme record | Tesamorelin | Phase 1 | Reported | Phase 1 ascending dose | — | 2010 | Very low |
| TESA-PIVOTAL-2-DDIprogramme record | Tesamorelin | Phase 1 | Reported | Randomised crossover | — | 2010 | Very low |
| TESA-PIVOTAL-1-QOLprogramme record | Tesamorelin | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2010 | Very low |